2013
The Combination Of Palbociclib Plus Bortezomib Is Safe and Active In Patients With Previously Treated Mantle Cell Lymphoma: Final Results Of a Phase I Trial
Martin P, DiLiberto M, Mason C, Ely S, Ruan J, Furman R, Chiron D, Huang X, Madoff D, Navi J, Lewis J, Bender A, Rodriguez A, Greenberg J, Coleman M, Chen-Kiang S, Leonard J. The Combination Of Palbociclib Plus Bortezomib Is Safe and Active In Patients With Previously Treated Mantle Cell Lymphoma: Final Results Of a Phase I Trial. Blood 2013, 122: 4393. DOI: 10.1182/blood.v122.21.4393.4393.Peer-Reviewed Original ResearchMantle cell lymphomaTreatment-related grade 3Dose level 3Dose level 4Dose level 1Phase I trialCombination of palbociclibGrade 3Day 8MCL cellsI trialCell lymphomaDose levelsCyclin D1Seattle GeneticsAdequate bone marrowDose level 2Dose of palbociclibNon-hematologic toxicitiesGrade 4 neutropeniaNausea/vomitingSpeakers bureauDuration of responseCycle 2Novel therapeutic combinations
2011
Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity
Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R. Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity. Molecular Cancer Therapeutics 2011, 10: 1300-1307. PMID: 21571911, DOI: 10.1158/1535-7163.mct-11-0259.Peer-Reviewed Original ResearchConceptsHepatic arterial infusionNab-paclitaxelHepatic extractionArterial infusionDose levelsNanoparticle Albumin-Bound PaclitaxelFirst-pass hepatic extractionPredominant liver metastasesCommon adverse eventsAdvanced cancer patientsAlbumin-Bound PaclitaxelDose-limiting toxicityPeak concentrationHighest dose levelStable diseaseAdverse eventsLiver involvementLiver metastasesPartial responseI trialComparative pharmacokinetic studyHepatic metastasesPoor outcomeCancer patientsNanoparticle albumin